About Indivior
Indivior is a publicly listed company based in Richmond Hill (United States) founded in 2014. Therapeutics for opioid addiction treatment are developed and commercialized. The company has 1,050 employees. Indivior has completed 1 acquisition, including Opiant Pharmaceuticals. Its website indivior.com draws about 33 thousand monthly visits. Indivior offers products and services including Addiction Recovery Treatments. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its legal entity is Indivior PLC. Its competitors include Braeburn, Cessation Therapeutics and Amygdala Neurosciences; 3 of its 3 listed competitors have raised funding.
Company details
Indivior was founded in 2014 and is headquartered in Richmond Hill, United States. Operations focus on the pharmaceutical sector, where drugs for addiction treatment are developed and commercialized. The portfolio consists of buprenorphine formulations, including sublingual films, tablets, and combinations with naloxone, all indicated for opioid substance abuse management. Activities span research, development, and market distribution in this specialized therapeutic area.
- Headquarters Richmond Hill, United States
- Employees 1,050
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website indivior.com/en
- Social LinkedIn X
- Legal Name Indivior Plc
- Annual Revenue$1.24 B (USD)4.29as on Dec 31, 2025
- Net Profit$210 M (USD)2900as on Dec 31, 2025
- EBITDA$378 M (USD)26.85as on Dec 31, 2025
- InvestorsNIH
& 1 more
- Employee Count1,050
- Investments & Acquisitions
Products & Services of Indivior
Indivior offers a comprehensive portfolio of products and services, including Addiction Recovery Treatments.
Medications aimed at supporting recovery from addiction and behavioral issues
Funding Insights of Indivior
- Total Rounds 2
- Investors Count 2
All 2 funding rounds of Indivior with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | Grant | – | – | ||
| Mar 2015 | Debt – Venture | – | – |
2 investors in total: 2 institutional.
Investors in Indivior
Indivior has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH and Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | athyrium.com | New York, United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Indivior
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Indivior
238 people are tracked at Indivior (127 in leadership, 9 in board & advisors, 102 in team); the tracked headcount is 1,050.
| Name | Role | Group |
|---|---|---|
Jim Moats | Access Director, Health Systems And Criminal Justice Systems | Leadership |
Lauren Church | US Head Of Logistics And Compliance | Leadership |
Edward McAdam | Director, Government Pricing, Contracting Operations And Analytics | Leadership |
Ryan McClelland | Director Of Market Access | Leadership |
Jennifer Vice | Associate Director | Leadership |
Kelli R. Casagrande | Area Sales Director | Leadership |
Matthew Ludwig | Area Sales Director | Leadership |
Jens Orphal | Head Of Field Force | Leadership |
Stephen Harrell | Area Sales Director | Leadership |
Johan V. | Associate Director - Business Analytics | Leadership |
Scot Johnston | Senior Access Director, Western Pennslyvania | Leadership |
Bob Fanning | Access Director, Health Systems | Leadership |
Anne le-Moigne | Vp, Clinical & Data Sciences And Operations | Leadership |
Luis Johnson | Associate Director Systems & Controls | Leadership |
Scott Carfagnini | Area Sales Director | Leadership |
Alix van Meerwijk | Global Program Director | Leadership |
Dmitry Bunich | Head Of Finance, Supply (director) | Leadership |
Lisa Toth | Access Director, Criminal Justice Systems | Leadership |
Bruce Gilbert | Sr. Area Sales Director | Leadership |
Doug Cobarras | Commercial Head Of Sales West Region | Leadership |
218 more people are available in the full profile.
Complete people profiles for Indivior
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Indivior
Indivior is a publicly listed company on the NASDAQ with ticker symbol INDV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Jan 2015
- Listed onNASDAQ: INDV
- Listed entityIndivior PLC
- Exchange sectorHealth technology
- ISINUS45579U1097
- Share price$35.42 (-1.77% on the day) · 2026-10-13
- Market capitalisation$4.18B
- Price to earnings12.6
- EPS (diluted, trailing year)$2.82
- Volume (last session)1,930,513
Financials of Indivior
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.24B | $210.0M | $378.0M |
| 2024 | $1.19B | $7.0M | $298.0M |
| 2023 | $1.09B | -$129.0M | $249.0M |
| 2022 | $901.0M | -$53.0M | $230.0M |
| 2021 | $791.0M | $205.0M | $209.0M |
Detailed financial statements for Indivior
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Indivior
Indivior has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Opiant Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for addictive and eating disorders are developed. | opiant.com | Santa Monica, United States | 2005 | Nov 2022 | $145M |
Complete acquisition details for Indivior
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Indivior
5 dated milestones of Indivior across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Indivior is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round.
- Funding Latest funding round, Grant,.
- Acquisition Acquires Opiant Pharmaceuticals.
Competitors of Indivior
Indivior has 3 listed competitors in our database, 3 of them funded. They include Braeburn, Cessation Therapeutics and Amygdala Neurosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| braeburnrx.com | 2012 | Philadelphia, United States | $110M | Long-acting therapies for opioid addiction and chronic pain are developed. | ||
| cessationtherapeutics.com | 2017 | San Jose, United States | $6.76M | Developer of immunotherapy based vaccines to manage addictions | ||
| amygns.com | 2015 | San Francisco, United States | $7.05M | Therapies for substance use disorders are developed by Amygdala Neurosciences. |
Detailed competitors of Indivior
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Indivior
The website of Indivior (indivior.com) receives about 33.3K visits a month and ranks #1,007,938 among all websites worldwide, #1,235 in Biotechnology and Pharmaceuticals.
- Monthly visits33.3K
▼ 0.6% vs previous month
- Unique visitors17.3K
per month
- Global rank#1,007,938
among all websites
- Category rank#1,235
Health · Biotechnology and Pharmaceuticals
- Bounce rate51%
- Pages per visit1.4
- Average visit16 sec
- DevicesDesktop 23% · Mobile 77%
Websites whose visitors overlap most with Indivior. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| salix.com | 100% | 15.6K | #1,433,848 | View details | |
| maynepharma.com | 98% | 18.6K | #918,677 | View details | |
| medpharm.com | 97% | 5.3K | #6,145,162 | View details | |
| catalent.com | 77% | 116.7K | #338,870 | View details | |
merzusa.com | merzusa.com | 67% | #2,673,211 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Indivior
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Indivior (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Indivior
Complete news archive for Indivior
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Indivior
Indivior was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Indivior is headquartered in Richmond Hill, United States. It is registered at Richmond Hill, Georgia, United States.
Indivior has 1,050 employees.
Annual revenue of Indivior is $1.24B as on Dec 31, 2025.
Indivior was founded in 2014 and is headquartered in Richmond Hill, United States. Operations focus on the pharmaceutical sector, where drugs for addiction treatment are developed and commercialized. The portfolio consists of buprenorphine formulations, including sublingual films, tablets, and combinations with naloxone, all indicated for opioid substance abuse management. Activities span research, development, and market distribution in this specialized therapeutic area.
Indivior's top competitors include Amygdala Neurosciences, Cessation Therapeutics and Braeburn.
Indivior offers Addiction Recovery Treatments.
Yes, Indivior is publicly traded on NASDAQ under the ticker symbol INDV.
Indivior has made 1 acquisition, including Opiant Pharmaceuticals.
Indivior has 2 investors. Key investors include NIH, and Athyrium Capital Management.
Indivior operates through Indivior Plc.